Pfizer chairman and CEO Albert Bourla joins ‘morning with Maria’ to discuss the $10 billion acquisition of Nogo Nordisk’s drug discovery and his plans to expand their drug pipeline.
PFizer Inc. is doubling down on the drug race, with CEO Albert Bourla announcing the company will be “strongly competitive” after securing a $10 billion deal to acquire metsera developer.
“PFIZER, when it plays, plays a lot, and we will, as we did with Covion, as in LIPITOT, as [with] Viagra, and all the drugs we have invented and brought to the market, we will do the same with obesity, “said Bourla on Thursday saying” in the morning with Maria. “
This agreement allows the pharmaceutical giant to secure the rights to a new weight loss treatment, entering a space already filled with popular GLP-1 drugs such as zevily’s zepbound and Nord Nordisk’s Wegovy.
PFizer expects to have its weight loss treatment on the market by the end of 2028, a move that could put it in a stake worth $150 to $200 billion.
PFizer wins $10b bidding war for Offsity Drug Developer Metsera in major pharmaceutical acquisition
A woman injects glp-1 into her abdomen in this undisclosed photo. (Stock / istock)
The Metsera agreement followed months of back and forth
Bourla said PFIZER received a “very good portfolio” from metsera, and will continue to build itself to be a “strong competitor” in the space.
The pharmaceutical giant, with its direct-to-consumer platform, is in line with the Trump Administration’s Push on the lower planets of the doctor, linking the TrumpPRRICT PREPTION to the TrumpPRRECT found to give American Proples access to medicines without depending on traditional minutes or middle men.
Batya Ungar-sargon: How Trump uses the same strategy to reduce big pharma, they are protected by peace
Various packages of a weight loss drug from the pharmaceutical company Norco Nordisk lie in a retail pharmacy in Copenhagen, Denmark on June 28, 2023. GLP-28 drugs, 2023. GLP-1 drugs, 2023. GLP-1 drugs have increased in popularity in recent years due to (Steffen TrumpF/Photo Alliance via Getty Images/Getty Images)
“I think trumprx is not just talking about a great opportunity for Americans to get medicine at a fraction of the cost,” Bourla said.
“That will create a very good momentum, and many patients who were leaving their prescriptions at the pharmacy because they could not afford them – now we will get more medicine.”
Bourla said the company will combine drugs with Trumprx’s drug access delivery system.
Find FOX business on the go by clicking here
Barron’s roundtable panel discusses the lack of labor data and offers advice on stocks that thrive during the shutdown.
“We’ll be able to have a complete website with all the 40-plus products we’re going to feature in this trumprx,” he shared.
“It will be ready in December so, when Trumprx is launched, it will be able to quickly send those to go on that website, on our website, so we can take care of everything.”
